News

Public · Published

Leerink Partners maintains Amgen at Market Perform, raises price target to $464 from $395

Leerink Partners maintained its Market Perform rating on Amgen and raised its price target to $464 from $395, a 17.5% increase. The target was roughly in line with Amgen's Nov. 5 closing price of $460.28.

Published:

Updated:

What happened

Leerink Partners maintained its Market Perform rating on Amgen and raised its price target to $464 from $395, a 17.5% increase. The target was roughly in line with Amgen’s Nov. 5 closing price of $460.28.

Confirmed

Global impact / market context

The higher target may influence how investors value Amgen, but the unchanged Market Perform rating signals no overall rating upgrade. Since the target is near the reported closing price, it indicates little difference between Leerink’s stated valuation and that recent price, which may temper immediate repositioning.

Analyst inference

Five recent analyst notes over 30 days set Amgen price targets between $435 and $530, so Leerink’s $464 sits within that range. Differences among targets and ratings can shape investor expectations, while revisions may affect buying or selling decisions and, in turn, share demand.

Analyst inference

What to watch

  1. Watch for future analyst changes to Amgen’s rating or target; repeated target increases could strengthen investor expectations and influence buying demand, while cuts could weaken them. Analyst inference
  2. Compare later targets with the reported $435–$530 range across five recent notes to see whether analyst valuations are narrowing or spreading, potentially changing investor positioning. Analyst inference
  3. Check whether Leerink changes its Market Perform rating in a later note, since the current update raised its price target but left the rating unchanged. Confirmed

Evidence

  • Original source link unavailable